Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
divalproex + phenytoin
- Development stage
- Unknown
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of two anticonvulsant medications that interact significantly when used together. Divalproex sodium (valproic acid) can displace phenytoin from plasma protein binding sites, increasing free phenytoin levels while potentially inhibiting its metabolism. This interaction can lead to phenytoin toxicity despite normal total phenytoin levels, requiring careful monitoring and potential dosage adjustments.
02
Targets
ABAT (4-aminobutyrate aminotransferase)NMDAR (Glutamate receptor ionotropic, NMDA)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on divalproex + phenytoin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on divalproex + phenytoin.